---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-034072"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:19:25.291054+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics appoints Binder and Wagner to Board; Singer and Cherington resign

## Summary
- Nicholas Singer and Charles Cherington resigned from Board on July 6, 2023; resignations not due to any disagreement.
- Board appointed Brant C. Binder (President, Bonito Biosciences) and Dr. Richard W. Wagner (CEO, Bonito Biosciences) to fill vacancies.
- Both new directors are independent under SEC/Nasdaq rules; Binder qualifies as audit committee financial expert.
- Binder and Wagner assigned to Audit, Compensation, and Nominating and Corporate Governance Committees.
- New directors will participate in standard non-employee director compensation arrangements.

## SEC filing metadata
- accession: 0001140361-23-034072
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/0001140361-23-034072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/brhc20055728_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-034072
- JSON: https://secwatch.observer/filing/0001140361-23-034072.json
- Plain text: https://secwatch.observer/filing/0001140361-23-034072.txt

## Key facts
- Executive change
  Brant C. Binder was appointed as Director at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On July 6, 2023, the Board appointed Mr. Brant C. Binder and Dr. Richard W. Wagner as directors, with effect immediately following the effectiveness of the resignations of Messrs. Singer and Cherington, to fill the vacancies on the Board created thereby.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/0001140361-23-034072-index.htm
- Executive change
  Richard W. Wagner was appointed as Director at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On July 6, 2023, the Board appointed Mr. Brant C. Binder and Dr. Richard W. Wagner as directors, with effect immediately following the effectiveness of the resignations of Messrs. Singer and Cherington, to fill the vacancies on the Board created thereby.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/0001140361-23-034072-index.htm
- Executive change
  Nicholas Singer resigned as Director at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: On July 6, 2023 Nicholas Singer and Charles Cherington resigned from the Board of Directors (the “ Board ”) of Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/0001140361-23-034072-index.htm
- Executive change
  Charles Cherington resigned as Director at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: On July 6, 2023 Nicholas Singer and Charles Cherington resigned from the Board of Directors (the “ Board ”) of Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/0001140361-23-034072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.